Urinary excretion of prostacyclin and thromboxane degradation products in patients with ovarian malignancy: effect of cytostatic treatment. by Aitokallio-Tallberg, A. et al.
Br. J. Cancer (1989), 60, 785-788
1989
Urinary excretion of prostacyclin and thromboxane degradation products
in patients with ovarian malignancy: effect of cytostatic treatment
A. Aitokallio-Tallberg', L. Viinikka2 & 0. Ylikorkala'
'First and Second Department ofObstetrics and Gynaecology and 2Children's Hospital, University ofHelsinki, Haartmaninkatu 2,
SF-00290, Helsinki, Finland.
Summary We studied the effect of ovarian cancer and its chemotherapy on the urinary excretion of
prostacyclin (PGI2) and thromboxane A2 (TxA2) hydration and metabolic products. In six patients we
measured 6-keto-PGF,a and 2,3-dinor-6-keto-PGF,. (PGI2 products) and thromboxane B2 (TxB2) and
2,3-dinor-TxB2 (TxA2 products) by HPLC followed by radioimmunoassay before, during and after the
combined infusion of cisplatin, 4'epi-adriamycin and cyclophosphamide. Before the first cytostatic infusion,
the urinary excretion of prostanoids was on average 4.4-5.8 times higher than in patients with ovarian
endometriosis (n= 19). The infusion ofcytostatics led to a 50-120% rise in the excretion ofprostanoids during
the first post-infusion 9 hours, but in the subsequent 10 hours their ouput was 25-45% below the initial value
and remained low for at least 2 weeks. Following repetitive courses ofcytostatics (2-4 per patient), prostanoid
excretion tended to normalise. These data suggest that ovarian cancer is associated with increased production
of PGI2 and TxA2, and that cytostatics suppress this production. This may be of biological significance in
tumour behaviour and in the effect of cytostatics.
Arachidonic acid metabolites can modulate cancer promo-
tion, growth, and spread (Karmali, 1983, 1987; Bennett,
1984; Deliconstantinos, 1987). Vasodilator, anti-aggregatory
prostacyclin (PG12) and vasoconstrictor, pro-aggregatory
thromboxane A2 (TxA2) are especially important in this
regard, since their balance may determine, at least partly, the
potential of some cancers to grow and spread. This theory
has been supported by some studies (Honn & Meyer, 1981
Honn et al., 1983a), but also disputed by other data (Stam-
ford et al., 1986). That prostaglandins and prostanoids may
be of significance for tumour behaviour gains support from
the data that prostaglandin synthesis inhibitors increase the
survival time of mice transplanted with mammary carcinoma
(Bennett et al., 1982). Ovarian cancer grows aggressively,
sends out metastases early and is often accompanied by deep
vein thrombosis (Fox, 1985); the latter phenomenon may well
be a sign of disturbed PGI2/TxA2 balance. We showed
recently that this cancer, as compared with healthy ovarian
tissue, produces in vitro an 11-fold excess of 6-keto-
prostagladin Fl,, (6-keto-PGFI,, the hydration product of
PGI2) and a 30-fold excess of thromboxane B2 (TxB2, the
hydration product of TxA2) (Aitokallio-Tallberg et al., 1988),
and that patients with ovarian cancer excrete increased
amounts of 6-keto-PGFIr. in their urine (Aitokallio-Tallberg
et al., 1987).
A combination of cisplatin, 4'epi-adriamycin and cyc-
lophosphamide is most often used for treating advanced
ovarian malignancy (Hainsworth et al.,1988). These agents
inhibit the division of cancer cells by disturbing DNA
double-helix formation (Chabner, 1982). Prostanoids can
influence cell growth and division, perhaps through cyclic
AMP (Gorman et al., 1977; Thaler-Dao et al., 1984).
It is well established that cytostatics can release various
classic prostaglandins in vitro (Berstock et al., 1979; Bennett
et al., 1982), but there are only a few data on the effect of
cytostatics on PGI2 and TxA2 production. High circulating
levels of 6-keto-PGFI,, and TxB2 in patients with
gynaecological malignancies (Ylikorkala et al., 1981; Alam et
al., 1982; Sundstrom et al., 1986) decreased following
administration of cytostatics by 30-40% (Ylikorkala et al.,
1981) or by 52% (Alam et al., 1982).
Currently, PGI2 and TxA2 production in vivo is best
assessed by measuring their urinary degradation products
(FitzGerald et al., 1983; Fischer et al., 1986; Ylikorkala et
al., 1986). The present study was designed to study the effect
of cisplatin, 4'epi-adriamycin and cyclophosphamide in com-
bination on the urinary output of PG12 and TxA2 degrada-
tion products in patients with ovarian cancer.
Patients and methods
Five patients with ovarian serous adenocarcinoma and one
with ovarian endometrioid adenocarcinoma were studied.
They were between 15 and 73 years of age (mean 51); three
were premenopausal and three post-menopausal. In two
women cancer was limited to the ovaries, but it had spread
to stage III -IV in four patients. Five patients had an
elevated (>65 IU ml-') cancer antigen 125 (CA-125) concen-
tration, measured immunoradiometrically (Centocor Inc.,
Malvern, PA, USA). The endometrioid cancer patient with
normal CA-125 had an increased (> 3fsg I') serum car-
cinoembryonic antigen concentration (CEA), measured
immunoradiometrically (Abbott Laboratories, North
Chicago, IL, USA). As the control group we studied 19
women with laparoscopically confirmed endometriosis
affecting the ovaries. They were between 22 and 43 years of
age (mean 33), and otherwise were healthy. The severity of
endometriosis was scored in the range from 5 to 80 points
(mean 28.9, American Fertility Society classification).
All cancer patients underwent laparotomy. Surgery was
radical (total hysterectomy with bilateral oophorectomy,
omental resection) only in the patient with endometrioid
cancer. In three patients most of the cancer tissue was
removed, but no resection was possible in the other two
cases.
All cancer patients received the same treatment, beginning
two weeks after surgery, with intravenous injection of cyc-
lophosphamide (500 mg m-2) and 4'epi-adriamycin
(40 mg m-2). Physiological saline (1000 ml) was infused con-
comitantly to guarantee adequate diuresis. Two or three
hours later cisplatin (50 mg m-2) was started as an int-
ravenous infusion over 5-7 hours; mannitol (15%, 500 ml
i.v.) and furosemide (20 mg i.m.) were also given. This
regimen was repeated on two to four occasions at 4-week
intervals, and altogether 19 courses were studied.
Urines were collected for: (1) 4-6 hours before the start of
cytostatics; (2) 5 hours from the start of the treatment; (3) 4
hours after the second sample; (4) 10 hours after the third
sample; (5) 4-6 hours 2 weeks later. In addition we collected
samples from four patients 4 weeks after the last cytostatic
treatment.
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The non-malignant control group collected their 24-hour
urines the day before laparoscopy. During the study no
subject took any drug (except for cytostatics) known to affect
prostanoid synthesis.
A 100 ml sample of each urine was frozen and stored at
-25C for 2-5 months until assayed for products of PGI2
(6-keto-PGFir. and 2,3-dinor-6-keto-PGF1,) and TxA2 (TxB2
and 2,3-dinor-TxB2). This storage does not affect the pros-
tanoids (Aitokallio-Tallberg et al., 1988). In brief, 10ml of
acidified urine (pH 3.0, IM HCI) were passed through Sep
Pak C18 cartridges (Waters Association, Milford, USA).
Retained prostanoids were eluted with ethyl acetate,
evaporated to dryness, and put through HPLC (water/
acetonitrile/acetic acid, 69.95:30.0:0.05, 2 ml min-'). After
2 min the first fraction (I) was collected over 1.5 min; this
contained 6-keto-PGFIj and dinor-TXB2. The second frac-
tion (II), collected for 3.5 min starting 0.25 min after the first
one, contained dinor-6-keto-PGFIr. and TxB2. Fraction I was
assayed for 6-keto-PGF1,, using 3H-6-keto-PGF10, as the
tracer, 6-keto-PGF,,, as the standard, and an antibody raised
against 6-keto-PGF1. in rabbits (Ylikorkala & Viinikka,
1981). For dinor-TxB2, 3H-TxB2 was used as the tracer,
dinor-TxB2 as the standard and rabbit TxB2 as the antibody
(Viinikka & Ylikorkala, 1980) because this antibody has
approximately 40% cross-reactivity with 2,3-dinor-TxB2.
Fraction II was assayed for TxB2 using 3H-TxB2 as the
tracer, TxB2 as the standard and TxA2 antibody (Viinikka &
Ylikorkala, 1980). For dinor-6-keto-PGFIm we used 3H-6-
keto-PGFI, as the tracer, dinor-6-keto-PGFI,, as the standard
and the 6-keto-PGFI. antibody (Ylikorkala & Viinikka,
1981) because this antibody has approximately 20% cross-
reactivity with 2,3-dinor-6-keto-PGFIg. The details of the
methods are give elsewhere (Ylikorkala et al., 1987). Pros-
tanoid excretion is expressed as pgmin-'.
At the end of each urine collection, serum and urine
creatinine were measured and the creatinine clearance deter-
mined.
The prostanoid excretion data are given as means ± s.e.
The significances of the difference were analysed by Student's
t test for paired and unpaired data as appropriate. To illus-
trate better the effect of cytostatics, the values during their
administration are given as percentages of the pretreatment
levels.
Results
Before cytostatics were given, the prostanoid excretion in
cancer patients was clearly higher than in the patients with
endometriosis (Table I). The increases were: 6-keto-PGFIr.
4.9-fold (P<0.0025), dinor-6-keto-PGFI, 4.4-fold
(P<0.002), TxB2 5.8-fold (P<0.0125) and dinor-TxB2 4.5-
fold (P<0.0005).
The cytostatic infusions were accompanied by a 50-120%
rise in the 5-h excretion of PGI2 and TxA2 products (Figure
1). This stimulation was strongest for 6-keto-PGFIc and TxB2
excretion. Between 9 and 19 h after the start of infusion the
excretion for all prostanoids was 35-45% below the pretreat-
ment levels. This reduction persisted for at least 2
weeks (Figure 1). The pattern of urinary prostanoid excretion
during infusion of cytostatics was constant from one course
to another.
Overall the amounts of PGI2 products fell after repetitive
courses with chemotherapy (Table I). This was not the case
in the output of TxA2 products which on average did not
change when the data following all cytostastic courses were
considered as a whole (Table I). However, when only the last
cytostastic course was considered, the excretion of TxA2
products decreased in four patients who responded
favourably to cytostatics, but remained high in two patients
who showed no response to treatment. There was also a
good correlation between decreases in serum CA-125 or CEA
levels and in urinary excretion of TxA2 products (Table II).
The mean creatinine clearance was approximately 20 ± 5%
lower 9 and 19 h after giving the cytostatics (P = 0.06, Figure
1). No significant relationship was seen between individual
prostanoid excretion and creatinine clearance, occurrence of
side-effects, or counts of leucocytes and platelets.
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Figure 1 Changes in urinary excretion of 6-keto-PGF1Im (0),
dinor-6-keto-PGF1,, (0), TxB2 (A), dinor-TxB2 (0) and creatinine
clearance (U) during the cytostatic treatment and two weeks later.
Values are percentages of initial levels (mean±s.e.). A, i.v. injection
of cyclophophamide and 4'epi-adriamycin; B, infusion with
physiological saline; C, i.m. injection of furosemide and i.v. infusion
of mannitol; D, i.v. cisplatin infusion.
Table I Urinary excretion of prostacyclin (PGI2) and thromboxane (TxA2) hydration and metabolic products (pgmin-',
mean± s.e.) in patients with ovarian cancer and endometriosis.
No. of
Subjects samples 6-keto-PGF,. Dinor-6-keto-PGFI, TxB2 Dinor-TxB2
Patients with ovarian cancer (n = 6)
before 1st cytostatic course 6 157.3±73.3ab 185.7+81.5cdc 80.2±54.0e 263.0±102.0f
before 2nd-5th cytostatic courses 17 42.9± 8.9b 58.2± 7.9d 81.2±60.0 259.0± 99.0
Patients with endometriosis (n = 19) 19 32.4± 4.5a 42.4± 3Ijc 13.8± 3.5e 57.9± 8.6'
Cancer patients excreted more urinary PGI2 and TxA2 products than did patients with endometriosis. Overall the amount of
PGI2 products fell after repetitive courses with chemotherapy (all data followingcytostatic courses are lumped together), but
the mean excretion ofTxA2 products did not change (see individual pre-treatment and post-treatment values in Table II).
ap <0.0025, bp <0.009, cp <0.002, dp <0.008, ep <0.0125, fP <0.0005.
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Table II Individual urinary prostanoid excretion (pgmin-')and serum Ca-125 (IU mlI) or CEA(jsgl') levels before the first and after the
last cytostatic course, and the clinical response to treatment.
6-keto-PGFI, Dinor-6-keto-PGFI, TxB2 Dinor-TxB2 Ca-125/CEA
Before After Before After Before After Before After Before After
the Ist the last the Ist the last the Ist the last the Ist the last the Ist the last Clinical
Patient cytostatic course cytostatic course cytostatic course cytostatic course cytostatic course response
1 63 27 94 82 31 21 160 169 279 30 80% reduction
in tumour size
2 135 45 150 68 19 24 196 330 3150 2500 no response
3 88 5 112 6 35 4 325 8 5440 100 tumour
disappeared
4 86 66 79 67 25 35 62 300 2604 3023 no response
5 519 18 590 10 350 8 740 52 250 29 tumour
disappeared
6 53 40 89 43 21 8 96 30 33 CEA 12 80% reduction
in tumour size
Theexcretion ofprostacyclin productsdecreased inallpatients, buttheexcretionofthromboxane productsdecreasedonlyin patientswho responded
favourably to treatment (patients 1, 3, 5 and 6).
Discussion
Through their effects on vascular wall-platelet interaction,
PGI2 and TxA2 may be important in cancer metastasis and
spread. It is generally thought that PGI2 or its dominance
over TxA2 should prevent metastasis (Honn et al., 1981,
1983b), but this theory has also been disputed (Stamford et
al., 1986). The picture may be partly unclear due to
difficulties in assessing PGI2 and TxA2 production in vivo.
Currently, in vivo PGI2 and TxA2 synthesis is usually studied
by measuring their urinary products (FitzGerald et al., 1983;
Fischer et al., 1986; Ylikorkala et al., 1986). Urinary 2,3-
dinor-6-keto-PGFIr. is considered the best index of systemic
PGI2 production (Rosenkranz et al., 1980; Brash et al., 1983),
whereas urinary 6-keto-PGF1,, may originate primarily from
the kidneys (Patrono et al., 1982). Circulating platelets are
the main source of urinary TxB2 and 2,3-dinor-TxB2 (Roberts
et al., 1981), although renal tissue may also produce them,
particularly TxB2 (Patrono et al., 1983). In the present work
we measured all four of these prostanoids.
The main purpose of this study was to evaluate the effects
of cytostatics on PGI2 and TxA2 pr(duction. Because inter-
individual variations in prostanoid excretion are large (Fis-
cher et al., 1986), we studied the effect ofrepetitive courses of
cytostatics. Previously we found increased urinary excretion
of 6-keto-PGF1,, in patients with ovarian malignancy
(Aitokallio-Tallberg et al., 1987). We now show that in these
patients 2,3-dinor-6-keto-PGFjg, TxB2 and 2,3-dinor-TxB2 are
also excreted excessively into urine. These rises are probably
in part related to the cancer, because they are higher than
those in the control group of patients with endometriosis
who may also have increased PGI2 and TxA2 production
(Dawood et al., 1984; Ylikorkala et al., 1984). We assume
that the excess prostanoids arise either from the cancer cells
(Aitokallio-Tallberg et al., 1988), or possibly in part
elsewhere in the body as a result of paraneoplastic changes.
The question of the role of prostanoid stimulation in the
growth and spread of ovarian cancer remains open.
Cytostatic therapy of ovarian cancer, applied in clinical
routine (Hainsworth et al., 1988), led similarly to a rise and
then a fall in the urinary output of PGI2 and TxA2 products.
Because the treatment did not alter renal function
significantly, the changes in urinary prostanoids presumably
reflect altered synthesis and/or release of PGI2 and TxA2
during cytostatic infusion. Cytostatics damage and/or kill
both cancerous and healthy cells, which may explain the
initial rise in prostanoid output in our work. Perhaps cell
death was so marked that it was reflected in later suppression
of prostanoid output. In the case of TxA2 suppression, a
decrease in platelet count induced by the cytostatics might be
a factor, although individual excretion and platelet counts
did not correlate. Furthermore, prostanoid excretion started
to decrease sooner than did platelet numbers, suggesting that
thrombopenia does not explain the suppression of TxA2 pro-
ducts.
We do not know which of the cytostatics caused pros-
tanoid changes. Although cytostatics, especially cisplatin,
affect renal tissue and function (Von Hoff & Rosencweig,
1979), creatinine clearance in out patients showed little or no
change. Furosemide could also have been a factor, because it
was reported to increase the output of PGI2 and TxA2 prod-
ucts (Wilson et al., 1983), but this was not confirmed by
others (Mackay et al., 1984; Franchi et al., 1987).
The most important finding of the present work was the
decrease in excretion of PGI2 and TxA2 products in patients
responding well to cytostatics, and the normalisation of ex-
cretion in many patients concomitantly with reduction in
tumour mass. This supports the role of prostanoids in cancer
(Honn & Meyer, 1981; Bennett, 1984). Of the two pros-
tanoids studied, TxA2 may be more important for the pro-
gress of ovarian cancer, since it remained unchanged in
patients who did not respond to chemotherapy.
In conclusion, patients with ovarian cancer excreted more
urinary PG12 and TxA2 products than did patients with
endometriosis. A combination of cisplatin, cyclophosphamide
and 4'epi-adriamycin initially stimulated these outputs, but
after repetitive courses caused a constant suppression.
This study was supported by grants from The Cancer Research
Foundation and Sigrid Juselius Foundation.
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